John Finn (PhD) is the Chief Scientific Officer (CSO) of Basecamp Research (BCR), a company at the intersection of Technology and Biology, dedicated to tackling the toughest challenges in life sciences by pushing the boundaries of known biology. John has >25 years of experience in the genetic medicine field, with a focus on genome editing and delivery technologies. Prior to BCR, John was the CSO of Tome Biosciences, a gene editing company focused on developing Programmable Genomic Integration (PGI) for the treatment of a broad range of diseases. Prior to Tome, John was Vice President of Discovery Research at Codiak Biosciences, where he led the development of a new class of therapeutics based on engineered exosomes. Prior to Codiak, John was Executive Director of Platform Biology and Liver Discovery at Intellia Therapeutics, where he was responsible for the development of viral and non-viral delivery systems and demonstrated the first in vivo systemic administration of CRISPR-based therapeutics. Previously, John served as Director of Research at Arthrogen, developing novel AAV and exosome-based therapeutics. He has served as an American Society of Gene and Cell Therapy (ASGCT) Committee Member for multiple committees, including Nanoagents and Synthetic Formulations; Genome Editing; Immune responses; and Metabolic and Inherited Disease. John trained with Pieter Cullis and Ian MacLachlan and received his PhD in Biochemistry and Molecular Biology from the University of British Columbia and BS in Molecular Biology and Genetics from the University of Guelph. He completed post-doctoral programs in Immunology and Vaccine research at McMaster University (Jonathan Bramson) and Hematology and Gene Therapy at the Children’s Hospital of Philadelphia (Kathy High, Valder Arruda).